188 related articles for article (PubMed ID: 8203856)
1. Rifabutin is active in murine models of toxoplasmosis.
Araujo FG; Slifer T; Remington JS
Antimicrob Agents Chemother; 1994 Mar; 38(3):570-5. PubMed ID: 8203856
[TBL] [Abstract][Full Text] [Related]
2. Use of rifabutin in combination with atovaquone, clindamycin, pyrimethamine, or sulfadiazine for treatment of toxoplasmic encephalitis in mice.
Araujo FG; Suzuki Y; Remington JS
Eur J Clin Microbiol Infect Dis; 1996 May; 15(5):394-7. PubMed ID: 8793398
[TBL] [Abstract][Full Text] [Related]
3. The activity of atovaquone (566C80) in murine toxoplasmosis is markedly augmented when used in combination with pyrimethamine or sulfadiazine.
Araujo FG; Lin T; Remington JS
J Infect Dis; 1993 Feb; 167(2):494-7. PubMed ID: 8421189
[TBL] [Abstract][Full Text] [Related]
4. Atovaquone maintenance therapy prevents reactivation of toxoplasmic encephalitis in a murine model of reactivated toxoplasmosis.
Dunay IR; Heimesaat MM; Bushrab FN; Müller RH; Stocker H; Arasteh K; Kurowski M; Fitzner R; Borner K; Liesenfeld O
Antimicrob Agents Chemother; 2004 Dec; 48(12):4848-54. PubMed ID: 15561866
[TBL] [Abstract][Full Text] [Related]
5. In vitro and in vivo activities of the hydroxynaphthoquinone atovaquone alone or combined with pyrimethamine, sulfadiazine, clarithromycin, or minocycline against Toxoplasma gondii.
Romand S; Pudney M; Derouin F
Antimicrob Agents Chemother; 1993 Nov; 37(11):2371-8. PubMed ID: 8285620
[TBL] [Abstract][Full Text] [Related]
6. Use of ketolides in combination with other drugs to treat experimental toxoplasmosis.
Araujo FG; Khan AA; Bryskier A; Remington JS
J Antimicrob Chemother; 1998 Nov; 42(5):665-7. PubMed ID: 9848454
[TBL] [Abstract][Full Text] [Related]
7. In vitro and in vivo effects of rifabutin alone or combined with atovaquone against Toxoplasma gondii.
Romand S; Della Bruna C; Farinotti R; Derouin F
Antimicrob Agents Chemother; 1996 Sep; 40(9):2015-20. PubMed ID: 8878573
[TBL] [Abstract][Full Text] [Related]
8. Activity of trovafloxacin in combination with other drugs for treatment of acute murine toxoplasmosis.
Khan AA; Slifer T; Araujo FG; Polzer RJ; Remington JS
Antimicrob Agents Chemother; 1997 May; 41(5):893-7. PubMed ID: 9145840
[TBL] [Abstract][Full Text] [Related]
9. Nonionic block copolymers potentiate activities of drugs for treatment of infections with Toxoplasma gondii.
Araujo FG; Slifer T
Antimicrob Agents Chemother; 1995 Dec; 39(12):2696-701. PubMed ID: 8593005
[TBL] [Abstract][Full Text] [Related]
10. Determination of parasitic burden in the brain tissue of infected mice in acute toxoplasmosis after treatment by fluconazole combined with sulfadiazine and pyrimethamine.
Sina S; Mohammad JM; Reza S; Anita M; Soudabeh E; Hadi M
Eur J Med Res; 2021 Jun; 26(1):65. PubMed ID: 34193287
[TBL] [Abstract][Full Text] [Related]
11. Toxoplasma gondii: the effect of fluconazole combined with sulfadiazine and pyrimethamine against acute toxoplasmosis in murine model.
Martins-Duarte ÉS; de Souza W; Vommaro RC
Exp Parasitol; 2013 Mar; 133(3):294-9. PubMed ID: 23270807
[TBL] [Abstract][Full Text] [Related]
12. Treatment with interleukin 12 in combination with atovaquone or clindamycin significantly increases survival of mice with acute toxoplasmosis.
Araujo FG; Hunter CA; Remington JS
Antimicrob Agents Chemother; 1997 Jan; 41(1):188-90. PubMed ID: 8980778
[TBL] [Abstract][Full Text] [Related]
13. Synergistic effect of clindamycin and atovaquone in acute murine toxoplasmosis.
Djurković-Djaković O; Nikolić T; Robert-Gangneux F; Bobić B; Nikolić A
Antimicrob Agents Chemother; 1999 Sep; 43(9):2240-4. PubMed ID: 10471572
[TBL] [Abstract][Full Text] [Related]
14. An ultrastructural study of the effect of treatment with atovaquone in brains of mice chronically infected with the ME49 strain of Toxoplasma gondii.
Ferguson DJ; Huskinson-Mark J; Araujo FG; Remington JS
Int J Exp Pathol; 1994 Apr; 75(2):111-6. PubMed ID: 8199003
[TBL] [Abstract][Full Text] [Related]
15. Atovaquone nanosuspensions show excellent therapeutic effect in a new murine model of reactivated toxoplasmosis.
Schöler N; Krause K; Kayser O; Müller RH; Borner K; Hahn H; Liesenfeld O
Antimicrob Agents Chemother; 2001 Jun; 45(6):1771-9. PubMed ID: 11353624
[TBL] [Abstract][Full Text] [Related]
16. A clinical-parasitological monotherapy cure in the treatment of experimental infection by a highly virulent strain of Toxoplasma gondii.
de Diego JA; Penin P; Arribas JR; Vázquez E; Vázquez JJ
Folia Microbiol (Praha); 1996; 41(6):513-6. PubMed ID: 9131805
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of atovaquone and sulfadiazine in the treatment of mice infected with Toxoplasma gondii strains isolated in Brazil.
Alves CF; Vitor RW
Parasite; 2005 Jun; 12(2):171-7. PubMed ID: 15991831
[TBL] [Abstract][Full Text] [Related]
18. Activity of clarithromycin alone or in combination with other drugs for treatment of murine toxoplasmosis.
Araujo FG; Prokocimer P; Lin T; Remington JS
Antimicrob Agents Chemother; 1992 Nov; 36(11):2454-7. PubMed ID: 1489188
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of sulfadiazine and pyrimetamine for treatment of experimental toxoplasmosis with strains obtained from human cases of congenital disease in Brazil.
Silva LA; Fernandes MD; Machado AS; Reis-Cunha JL; Bartholomeu DC; Almeida Vitor RW
Exp Parasitol; 2019 Jul; 202():7-14. PubMed ID: 31077733
[TBL] [Abstract][Full Text] [Related]
20. The timing of sulfadiazine therapy impacts the reactivation of latent Toxoplasma infection in IRF-8-/- mice.
Jost C; Reiter-Owona I; Liesenfeld O
Parasitol Res; 2007 Nov; 101(6):1603-9. PubMed ID: 17846793
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
